Loading...
•
Mar 31
Evolus Q1 2025 Earnings Report
Estimated Revenue:$76.9M
+33.3% YoY
Estimated EPS:-$0.0101
+86.0% YoY
Key Takeaways
Evolus reported global net revenue of $68.5 million for Q1 2025, a 15.5% increase year-over-year, driven by strong Jeuveau® demand and market share gains. The company launched Evolysse™ in the U.S. in Q2 and remains on track to achieve positive non-GAAP operating income for the full year 2025.
Global net revenue for Q1 2025 was $68.5 million, an increase of 15.5% from Q1 2024.
GAAP operating loss for the first quarter was $15.2 million.
Non-GAAP operating loss for the first quarter was $5.5 million.
Evolysse™ was launched in Q2 and is showing strong early adoption.
Evolus
Evolus
Evolus Revenue by Segment
Revenue by Segment
Service Revenue
CapyFin.com Forward Guidance
Evolus reaffirmed its full-year 2025 net revenue guidance and expects to achieve positive non-GAAP operating income in Q4 2025, with contributions from new HA gels.
Positive Outlook
- Reaffirms 2025 net revenue guidance of $345 million to $355 million.
- Anticipates achieving positive non-GAAP operating income on a consolidated basis for the full-year 2025.
- Evolysse™ and Estyme® injectable HA gels anticipated to contribute 8 to 10% of total revenue for the full-year 2025.
- Anticipates achieving non-GAAP operating income margins of at least 20% by 2028.
- Total net revenue of at least $700 million by 2028, a compound annual growth rate of 27% from 2024.
Challenges Ahead
- Non-GAAP operating income is anticipated to be generated in Q4 2025.
- Full-year non-GAAP operating expenses for 2025 expected to be between $230 million and $240 million.
- Investments in expanding Jeuveau® and scaling Nuceiva® internationally will continue.
- Supporting the launch of Evolysse™ and Estyme® injectable HA gels will contribute to expenses.
- Launch of Evolysse™Sculpt and Evolysse™Lips are in 2026 and 2027, respectively.